PolyPid (PYPD)

Name: PolyPid (PYPD) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: PolyPid (PYPD)

Stock Card

$5.11

$0.01 (0.20%)

As on 26-Aug-2026 16:00EDT

Market cap

$104 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

19.2

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

PolyPid (PYPD) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.97 High: 5.23

52 Week Range

Low: 3.06 High: 5.73

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-2.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.4
Debt to Equity

0
Book Value

$--
EPS

$-1.5
Face value

--
Shares outstanding

20,311,766

9 Years Aggregate

CFO

$-168.19 Mln

EBITDA

$-231.50 Mln

Net Profit

$-202.86 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
PolyPid (PYPD)	17.7	31.0	1.8	48.1	-19.0	-54.2	--
BSE Sensex^*	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 26-Aug-2026 | *As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021
PolyPid (PYPD)	42.8	-81.8	-87.8	-42.0
S&P Small-Cap 600	4.0	13.9	-17.4	25.3
BSE Sensex	9.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
PolyPid (PYPD)	5.1	103.6	0.0	-31.5	--	-385.1	--	19.2
Kamada - ADR	8.4	475.4	191.9	22.3	13.9	8.3	21.7	1.8
MediWound - ADR	12.7	170.5	11.9	-20.2	-176.1	-50.9	--	4.8

Shareholding Pattern

View Details

About PolyPid (PYPD)

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product... candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Read more

CEO & Director

Ms. Dikla Czaczkes Akselbrad
CEO & Director

Ms. Dikla Czaczkes Akselbrad
Headquarters

Petah Tikva
Website

https://www.polypid.com

FAQs for PolyPid (PYPD)

What is the current share price of PolyPid (PYPD) Today?

The share price of PolyPid (PYPD) is $5.11 (NASDAQ) as of 26-Aug-2026 16:00 EDT. PolyPid (PYPD) has given a return of -18.97% in the last 3 years.

What is the current PB & PE ratio of PolyPid (PYPD)?

Since, TTM earnings of PolyPid (PYPD) is negative, P/E ratio is not available.
The P/B ratio of PolyPid (PYPD) is 19.23 times as on 21-Aug-2026, a 303 premium to its peers’ median range of 4.77 times.

PE & PB ratio at the end of financial year.